In an effort to help save lives of Black and Brown Californians who have been hit disproportionately hard by the COVID-19 pandemic, Governor Gavin Newsom has announced a new pledge to allocate up to 40% of existing vaccine doses to the state’s underserved communities. Health officials in the state hope…
Tag: vaccine
Nearly Half of US Vaccine Records Lack Crucial Data on Recipient Race
With racial disparities in the distribution of the currently approved COVID-19 vaccines already being a known problem, a new issue has also arisen in the fight against the coronavirus: lack of accurate vaccination data. Akilah Johnson from The Washington Post has reported that “Race and ethnicity data was missing for…
Ex-Michigan Governor Charged for Racist Lead Poisoning of Flint Water Supply; COVID-19 Vaccines Not Increasing in Availability; Democrats Plan to Repeal Trump Rules; and More
Former Michigan Governor formally charged for poisoning thousands of predominantly Black Flint citizens with water containing lead. In 2014, when the city of Flint was forced by the state to begin taking its water supply from the Flint river rather than using water from nearby Detroit as it had for…
The US Breaks Its Record for Daily COVID-19 Deaths — Again; New Hope in Reuniting Immigrant Families Separated by Trump Administration at the Border; and More
The U.S. breaks its record for daily COVID-19 deaths. Again. The United States has surpassed 14 million cases of COVID-19 infection (less than a week after hitting the 13-million milestone) and things are looking even grimmer as the country heads into the winter season. More troublingly, The New York Times…
Johnson & Johnson Announces Agreement with U.S. Government for 100 Million Doses of Investigational COVID-19 Vaccine
Johnson & Johnson (NYSE: JNJ) (the Company) today announced its Janssen Pharmaceutical Companies have entered into an agreement with the U.S. government for the large scale domestic manufacturing and delivery in the U.S. of 100 million doses of Janssen’s SARS-CoV-2 investigational vaccine, Ad26.COV2.S, for use in the United States following approval or Emergency Use Authorization by the U.S. Food and Drug Administration (FDA).
As COVID-19 Vaccine Trials Commence, Diversity Becomes a Vital Issue
As the COVID-19 pandemic disproportionately impacts diverse communities, the need for greater diversity in vaccine trials is very evident. Black and Latinx people have been three times as likely as white people to be infected with the virus, and twice as likely to die, but they have historically made up…
Sanofi and GSK to Join Forces in Unprecedented Vaccine Collaboration to Fight COVID-19
Originally published on sanofi.com. Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19 Companies to combine innovative technologies to develop an adjuvanted COVID-19 vaccine Candidate vaccine expected to enter clinical trials in the second half of 2020 and, if successful, to be available in the second…
Johnson & Johnson Announces ‘Road to a Vaccine’ Live Series to Document Fight Against COVID-19
Johnson & Johnson announced the launching of an eight-week-long educational live series hosted by producer and journalist Lisa Ling. The series will address the COVID-19 crisis and highlight global efforts to develop a vaccine and treatment options. Beginning April 14, every Tuesday, Johnson & Johnson will broadcast the series live…
Johnson & Johnson Working to Develop Potential Vaccine for COVID-19
Johnson & Johnson (A DiversityInc Hall of Fame Company) announced it has a lead candidate for a potential vaccine for COVID-19, the pandemic sweeping the world and killing thousands. “The world is facing an urgent public health crisis and we are committed to doing our part to make a COVID-19 vaccine available…
Sanofi: FDA approves Fluzone® High-Dose Quadrivalent (Influenza Vaccine) for adults 65 years of age and older
Originally published on Sanofi.com. The U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application for Fluzone® High-Dose Quadrivalent (Influenza Vaccine) for use in adults 65 years of age and older. Fluzone® High-Dose (Influenza Vaccine) was approved by the FDA in 2009 as a trivalent influenza vaccine, including two…